Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Encircling the regions of the pharmacogenomic landscape that determine drug response.

Fernández-Torras A, Duran-Frigola M, Aloy P.

Genome Med. 2019 Mar 26;11(1):17. doi: 10.1186/s13073-019-0626-x.

2.

Exploring the OncoGenomic Landscape of cancer.

Mateo L, Guitart-Pla O, Duran-Frigola M, Aloy P.

Genome Med. 2018 Aug 3;10(1):61. doi: 10.1186/s13073-018-0571-0.

3.

Systems analysis of intracellular pH vulnerabilities for cancer therapy.

Persi E, Duran-Frigola M, Damaghi M, Roush WR, Aloy P, Cleveland JL, Gillies RJ, Ruppin E.

Nat Commun. 2018 Jul 31;9(1):2997. doi: 10.1038/s41467-018-05261-x.

4.

Rationalizing Drug Response in Cancer Cell Lines.

Juan-Blanco T, Duran-Frigola M, Aloy P.

J Mol Biol. 2018 Sep 14;430(18 Pt A):3016-3027. doi: 10.1016/j.jmb.2018.03.021. Epub 2018 Apr 4.

PMID:
29626539
5.

Detecting similar binding pockets to enable systems polypharmacology.

Duran-Frigola M, Siragusa L, Ruppin E, Barril X, Cruciani G, Aloy P.

PLoS Comput Biol. 2017 Jun 29;13(6):e1005522. doi: 10.1371/journal.pcbi.1005522. eCollection 2017 Jun.

6.

A PanorOmic view of personal cancer genomes.

Mateo L, Guitart-Pla O, Pons C, Duran-Frigola M, Mosca R, Aloy P.

Nucleic Acids Res. 2017 Jul 3;45(W1):W195-W200. doi: 10.1093/nar/gkx311.

7.

Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.

Yang X, Coulombe-Huntington J, Kang S, Sheynkman GM, Hao T, Richardson A, Sun S, Yang F, Shen YA, Murray RR, Spirohn K, Begg BE, Duran-Frigola M, MacWilliams A, Pevzner SJ, Zhong Q, Trigg SA, Tam S, Ghamsari L, Sahni N, Yi S, Rodriguez MD, Balcha D, Tan G, Costanzo M, Andrews B, Boone C, Zhou XJ, Salehi-Ashtiani K, Charloteaux B, Chen AA, Calderwood MA, Aloy P, Roth FP, Hill DE, Iakoucheva LM, Xia Y, Vidal M.

Cell. 2016 Feb 11;164(4):805-17. doi: 10.1016/j.cell.2016.01.029.

8.

Systems-Wide Prediction of Enzyme Promiscuity Reveals a New Underground Alternative Route for Pyridoxal 5'-Phosphate Production in E. coli.

Oberhardt MA, Zarecki R, Reshef L, Xia F, Duran-Frigola M, Schreiber R, Henry CS, Ben-Tal N, Dwyer DJ, Gophna U, Ruppin E.

PLoS Comput Biol. 2016 Jan 28;12(1):e1004705. doi: 10.1371/journal.pcbi.1004705. eCollection 2016 Jan.

9.

Residues Coevolution Guides the Systematic Identification of Alternative Functional Conformations in Proteins.

Sfriso P, Duran-Frigola M, Mosca R, Emperador A, Aloy P, Orozco M.

Structure. 2016 Jan 5;24(1):116-126. doi: 10.1016/j.str.2015.10.025. Epub 2015 Dec 10.

10.

Isolation of Human Colon Stem Cells Using Surface Expression of PTK7.

Jung P, Sommer C, Barriga FM, Buczacki SJ, Hernando-Momblona X, Sevillano M, Duran-Frigola M, Aloy P, Selbach M, Winton DJ, Batlle E.

Stem Cell Reports. 2015 Dec 8;5(6):979-987. doi: 10.1016/j.stemcr.2015.10.003. Epub 2015 Nov 5.

11.

Drug sensitivity in cancer cell lines is not tissue-specific.

Jaeger S, Duran-Frigola M, Aloy P.

Mol Cancer. 2015 Feb 15;14:40. doi: 10.1186/s12943-015-0312-6.

12.

Systematic identification of molecular links between core and candidate genes in breast cancer.

Arroyo R, Suñé G, Zanzoni A, Duran-Frigola M, Alcalde V, Stracker TH, Soler-López M, Aloy P.

J Mol Biol. 2015 Mar 27;427(6 Pt B):1436-1450. doi: 10.1016/j.jmb.2015.01.014. Epub 2015 Jan 29.

PMID:
25640309
13.

A chemo-centric view of human health and disease.

Duran-Frigola M, Rossell D, Aloy P.

Nat Commun. 2014 Dec 1;5:5676. doi: 10.1038/ncomms6676.

14.

IntSide: a web server for the chemical and biological examination of drug side effects.

Juan-Blanco T, Duran-Frigola M, Aloy P.

Bioinformatics. 2015 Feb 15;31(4):612-3. doi: 10.1093/bioinformatics/btu688. Epub 2014 Oct 17.

PMID:
25380960
15.

Charting the molecular links between driver and susceptibility genes in colorectal cancer.

Arroyo R, Duran-Frigola M, Berenguer C, Soler-López M, Aloy P.

Biochem Biophys Res Commun. 2014 Mar 21;445(4):734-8. doi: 10.1016/j.bbrc.2013.12.012. Epub 2014 Jan 9.

PMID:
24412244
16.

Modifications of microvascular EC surface modulate phototoxicity of a porphycene anti-ICAM-1 immunoconjugate; therapeutic implications.

Rosàs E, Santomá P, Duran-Frigola M, Hernandez B, Llinàs MC, Ruiz-González R, Nonell S, Sánchez-García D, Edelman ER, Balcells M.

Langmuir. 2013 Aug 6;29(31):9734-43. doi: 10.1021/la401067d. Epub 2013 Jul 26.

17.

Structural systems pharmacology: the role of 3D structures in next-generation drug development.

Duran-Frigola M, Mosca R, Aloy P.

Chem Biol. 2013 May 23;20(5):674-84. doi: 10.1016/j.chembiol.2013.03.004. Review.

18.

Analysis of chemical and biological features yields mechanistic insights into drug side effects.

Duran-Frigola M, Aloy P.

Chem Biol. 2013 Apr 18;20(4):594-603. doi: 10.1016/j.chembiol.2013.03.017.

19.

Recycling side-effects into clinical markers for drug repositioning.

Duran-Frigola M, Aloy P.

Genome Med. 2012 Jan 27;4(1):3. doi: 10.1186/gm302.

20.

Dual fluorescence in 9-amino-2,7,12,17-tetraphenylporphycene.

Duran-Frigola M, Tejedor-Estrada R, Sánchez-García D, Nonell S.

Phys Chem Chem Phys. 2011 Jun 7;13(21):10326-32. doi: 10.1039/c0cp02654a. Epub 2011 Apr 26.

PMID:
21523274

Supplemental Content

Loading ...
Support Center